Trials / Completed
CompletedNCT00660335
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Repligen Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of RG1068 (synthetic human secretin) with MRCP in subjects with abnormalities of the pancreas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RG1068 (synthetic human secretin) | Single-dose, IV infusion |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2008-04-17
- Last updated
- 2009-12-03
Source: ClinicalTrials.gov record NCT00660335. Inclusion in this directory is not an endorsement.